论文部分内容阅读
目的探讨IL-33、ST2在慢性阻塞性肺疾病(COPD)急性加重患者中的表达及其意义。方法选取2010年12月至2012年12月COPD急性加重患者30例为病例组,匹配同期健康体检者30例为对照组。使用ELISA法测定治疗前后血清、痰液中IL-33和ST2的表达,并收集患者住院期间肺功能、血气分析、血常规、C反应蛋白(CRP)等临床相关资料进行分析。结果病例组治疗前血清ST2水平显著高于对照组,差异有统计学意义(P<0.05);而痰液ST2、痰液IL-33以及血清IL-33在两组比较中均无统计学差异(均P>0.05)。治疗后病例组血清ST2水平显著低于治疗前(P<0.05),与对照组比较无统计学差异(P>0.05)。病例组治疗后IC%显著性升高(P<0.05),同时CRP显著降低P<0.05)。相关性分析发现血清ST2与IC%、FEV_1%呈显著负相关(均P<0.05),与CRP、二氧化碳分压(PCO_2)、氧分压(PO_2)、乳酸(LA)及血白细胞(WBC)未发现有明显相关性(均P>0.05)。结论血清ST2水平在COPD急性加重期明显增高,治疗缓解后显著降低,并可恢复正常。血清ST2可作为判断COPD病情变化的一项血清生物标志物。
Objective To investigate the expression and significance of IL-33 and ST2 in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods Thirty patients with acute exacerbation of COPD from December 2010 to December 2012 were selected as the case group and 30 healthy people as the control group. The levels of IL-33 and ST2 in serum and sputum before and after treatment were measured by ELISA, and the clinical data such as pulmonary function, blood gas analysis, blood routine and C-reactive protein (CRP) during hospitalization were collected for analysis. Results The level of serum ST2 in patients before treatment was significantly higher than that in the control group (P <0.05). However, the levels of ST2, IL-33 in sputum and IL-33 in serum were not significantly different between the two groups (All P> 0.05). After treatment, the level of serum ST2 in patients was significantly lower than that before treatment (P <0.05), and there was no significant difference between the two groups (P> 0.05). After treatment, IC% of patients in treatment group increased significantly (P <0.05), and CRP decreased significantly (P <0.05). Correlation analysis showed that there was a significant negative correlation between serum ST2 and IC% and FEV_1% (all P <0.05) and CRP, PCO_2, PO_2, LA and WBC, No significant correlation was found (all P> 0.05). Conclusions The level of serum ST2 in acute exacerbation of COPD increased significantly after treatment was significantly reduced, and returned to normal. Serum ST2 can be used as a serum biomarker to judge the change of COPD.